186 related articles for article (PubMed ID: 29251788)
1. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
Quinet J; Jamard C; Burtin M; Lemasson M; Guerret S; Sureau C; Vaillant A; Cova L
Hepatology; 2018 Jun; 67(6):2127-2140. PubMed ID: 29251788
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.
Noordeen F; Scougall CA; Grosse A; Qiao Q; Ajilian BB; Reaiche-Miller G; Finnie J; Werner M; Broering R; Schlaak JF; Vaillant A; Jilbert AR
PLoS One; 2015; 10(11):e0140909. PubMed ID: 26560490
[TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
[TBL] [Abstract][Full Text] [Related]
6. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
7. An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients.
Debing Y; Vanrusselt H; Degrauwe L; Silva de Oliveira DA; Kariuki CK; Ebwanga EJ; Bashir S; Merckx W; Thatikonda SK; Rajwanshi V; Gohil V; Hong J; Kum DB; Acosta Sanchez A; Chanda S; Blatt LM; Jekle A; Symons JA; Smith DB; Raboisson P; Lin TI; Beigelman L; Paeshuyse J
Antiviral Res; 2024 Apr; 224():105835. PubMed ID: 38401714
[TBL] [Abstract][Full Text] [Related]
8. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
Le Guerhier F; Thermet A; Guerret S; Chevallier M; Jamard C; Gibbs CS; Trépo C; Cova L; Zoulim F
J Hepatol; 2003 Mar; 38(3):328-34. PubMed ID: 12586299
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
11. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.
Noordeen F; Vaillant A; Jilbert AR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5299-306. PubMed ID: 23939904
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
Chen X; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
14. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
[TBL] [Abstract][Full Text] [Related]
15. [Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo].
Chen Y; Guo S; Qi Z; Huang A
Zhonghua Gan Zang Bing Za Zhi; 2001 Aug; 9(4):209-11. PubMed ID: 11602049
[TBL] [Abstract][Full Text] [Related]
16. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
[TBL] [Abstract][Full Text] [Related]
18. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
20. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]